Regenerative medicine and tissue engineering have seen unprecedented growth in the past decade, driving the field of artificial tissue models towards a revolution in future medicine. 3D bioprinting is gaining momentum in many medicinal applications to address the need for complex scaffolds required for generation of tissues and organs suitable for transplantation.
CollPlant’s rhCollagen-based BioInks offer ideal characteristics for 3D bioprinting, including optimal rheology, increased safety profile, biocompatibility and tuneable physical properties.
CollPlant is advancing the development of 3D bioprinted tissues and organs, in-house and in collaboration with partners.
In October 2018, we entered into a licensing agreement with United Therapeutics, a leader in the field, for use of CollPlant’s BioInks for the manufacture of 3D bioprinted lungs for transplant in humans. In September 2020, the collaboration was expanded to include 3D bioprinting of human kidneys for transplant.
30,000 organ transplants are done each year in the US, while 900,000 people die every year due to organ impairment. 3D bioprinting is expected to bridge this gap by allowing an unlimited supply of life-saving organs.